{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"4"}]}],"title":"Treatment emergent AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}]}],"title":"Treatment related AE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. An AE was considered treatment emergent if the event occurred during the on-treatment period (regardless of if it was seen prior to the start of treatment). An AE was considered treatment related as assigned by the investigator.","groups":[{"description":"Participants received glasdegib 100 milligrams (mg) tablet per oral (PO) once a day (QD) in combination with azacitidine 75 mg per meter squared (m\\^2)/day as subcutaneous (SC) injection or intravenous (IV) infusion for 7 days every 28 days. Treatment continued until objective disease progression or relapse, death, unacceptable toxicity, or participant refusal, whichever occurred first. Participants were followed up for 28 days after end of study treatment.","id":"OG000","title":"Glasdegib + Azacitidine"},{"description":"Participants received placebo matched to Glasdegib in combination with azacitidine 75mg/m\\^2/day SC or IV for 7 days every 28 days. Treatment continued until objective disease progression or relapse, death, unacceptable toxicity, or participant refusal, whichever occurred first. Participants were followed up for 28 days after end of study treatment.","id":"OG001","title":"Placebo + Azacitidine"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all participants who receive at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"From initiation of study treatment to study completed from 17-May-2021 to 02-Dec-2022 (approximately 565 days)","title":"Number of Participants With Treatment Emergent Adverse Event (AE) and Treatment Related AE","type":"PRIMARY","unitOfMeasure":"Participants"}